Showing 1971-1980 of 5957 results for "".
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p
- Haag-Streit Launches Cornea Map Toric Assessment Feature for the Lenstarhttps://modernod.com/news/haag-streit-launches-cornea-map-toric-assessment-feature-for-the-lenstar/2482833/Haag-Streit has unveiled the the cornea map for its flagship Lenstar 900 optical biometer. This feature is designed to provide clinic
- FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu Lens System in Patients with Cataractshttps://modernod.com/news/fda-grants-atia-vision-approval-to-begin-us-clinical-trial-of-omnivu-lens-system-in-patients-with-cataracts/2482811/Atia Vision has received Investigational Device Exemption (IDE) approval from the FDA to begin a traditional feasibility clinical study of its OmniVu Lens System. This novel IOL is designed to restore dynamic range of vision following catar
- Medical Journals Cite “Harassment” After Increased Scrutiny from Justice Departmenthttps://modernod.com/news/medical-journals-cite-harassment-after-increased-scrutiny-from-justice-department/2482762/At least three major medical journals have reported receiving a letter from the U.S. Department of Justice (DOJ) that questioned their editorial practices and st
- BVI Medical Receives FDA 510(k) Clearance for the Leos Laser Endoscopy Ophthalmic Systemhttps://modernod.com/news/bvi-medical-announces-fda-510k-clearance-of-the-leos-laser-endoscopy-ophthalmic-system/2482743/BVI Medical has received 510(k) clearance from the FDA for its glaucoma surgical system, Leos (Laser Endoscopy Ophthalmic System). Leos introduces a novel, intuitive laser ECP procedure designed to integrate seamlessly into the surgical workflow. According to BVI, it
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Bausch + Lomb Launches Arise Orthokeratology Lens System in the UShttps://modernod.com/news/bausch-lomb-announces-arisetm-orthokeratology-lens-system-in-the-united-states/2482702/Bausch + Lomb announced the US launch of Arise, a lens fitting system designed to use intelligent, cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology is a non-surgical method of vision correction that uses rigid, gas-permea
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g